<DOC>
	<DOC>NCT01814839</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-TTRSC (revusiran) in healthy volunteer subjects.</brief_summary>
	<brief_title>A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Body mass index (BMI) must be ≥ 16.5 kg/m2 and ≤ 35.0 kg/m2; Female subjects must be of nonchildbearing potential; e.g., postmenopausal or premenopausal with surgical sterilization; Male subjects agree to use appropriate contraception; Adequate blood counts, liver and renal function; Nonsmokers for at least 3 months; Willing to give written informed consent and are willing to comply with the study requirements; Subject was born in Japan and has lived outside of Japan for &lt;10 years, and subject's biological parents and grandparents are fully Japanese and were born in Japan (cohorts 19 and 20). Known human immunodeficiency virus (HIV) positive status or known or suspected systemic bacterial, viral, parasitic, or fungal infection; Subjects with a history of multiple drug allergies or intolerance to SC injection; History of drug abuse and/or alcohol abuse; Receiving an investigational agent within 3 months prior to study drug administration; Considered unfit for the study by the Principal Investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
</DOC>